Jump to content

Side effects of bicalutamide

From Wikipedia, the free encyclopedia

Major side effects of bicalutamide[1][2][3][4][5][6][7]
Frequency Class of effect Effect
Very common (≥10%) Reproductive system and breast disorders • Breast tenderness[a]
• Gynecomastia[a]
Common (1–10%) General and psychiatric disorders • Asthenia
• Decreased libido
• Erectile dysfunction
• Hot flashes
Skin and subcutaneous
tissue disorders 		• Decreased body hair
Hepato-biliary disorders • Elevated liver enzymes[b]
Uncommon (0.1–1%) Immune system disorders and hypersensitivity reactions • Angioedema
• Hives
Rare (<0.1%) or unknown Respiratory disorders • Lung disease[c]
Skin and subcutaneous tissue disorders • Sensitivity to light
Hepato-biliary disorders • Liver toxicity[c]
  1. ^ a b May occur as often as 90% of those taking bicalutamide, but is mild-to-moderate in 90% of occurrences. Incidence greatly decreased in combination with castration.
  2. ^ Usually transient, rarely severe. Resolves or improves with continued therapy or on discontinuation.
  3. ^ a b Reported in single cases, but not observed in any large, randomized trial. With regular liver monitoring and discontinuation as needed.

The side effects of bicalutamide, a nonsteroidal antiandrogen (NSAA), including its frequent and rare side effects, have been well-studied and characterized. The most common side effects of bicalutamide monotherapy in men include breast tenderness, breast growth, feminization, demasculinization, and hot flashes. Less common side effects of bicalutamide monotherapy in men include sexual dysfunction, depression, fatigue, weakness, and anemia. Bicalutamide is well tolerated and has few side effects in women. General side effects of bicalutamide that may occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash.

In men with prostate cancer, bicalutamide monotherapy has been found to increase the likelihood of death due to causes other than prostate cancer. Bicalutamide has been found to cause unfavorable liver changes in around 3 to 11% of people, with such changes necessitating discontinuation in approximately 1%. Rarely, bicalutamide has been associated with serious liver toxicity and lung disease, as well as sensitivity to light. It has also uncommonly been associated with hypersensitivity reactions. Bicalutamide has a theoretical risk of birth defects in male fetuses.

Central nervous system

[edit]

Hot flashes

[edit]

In the Early Prostate Cancer (EPC) clinical trial programme, at 7.4 years follow-up, the rate of hot flashes was 9.2% for bicalutamide monotherapy relative to 5.4% for placebo, which was regarded as relatively low.[8] In the LAPC subgroup of the EPC trial, the rate of hot flashes with bicalutamide monotherapy was 13.1% (relative to 50.0% for castration).[8][9]

Sexual dysfunction

[edit]

Bicalutamide may cause sexual dysfunction, including decreased sex drive and erectile dysfunction.[8] However, the rates of these side effects with bicalutamide monotherapy are very low.[8] In the EPC trial, at 7.4 years follow-up, the rates of decreased libido and impotence were only 3.6% and 9.3% in the 150 mg/day bicalutamide monotherapy group relative to 1.2% and 6.5% for placebo, respectively.[8] Similarly, in the trials of 150 mg/day bicalutamide monotherapy for advanced prostate cancer, fewer than 10% of men reported decreased sex drive or reduced erectile function as a side effect.[9] About two-thirds of men in these trials, who had advanced prostate cancer and were of almost invariably advanced age,[10] maintained sexual interest, while sexual function was slightly reduced by 18%.[9] Most men experience sexual dysfunction only moderately or not at all with bicalutamide monotherapy, and the same is true during monotherapy with other NSAAs.[11] Bicalutamide monotherapy at a dosage of 50 mg/day had no effect on nocturnal erections in men with prostate cancer.[12][13] The preservation of sexual desire and function with NSAA monotherapy may be related to testosterone metabolites such as estradiol and the 3α-androstanediol maintaining these functions rather than the androgen receptor or to bicalutamide and other NSAAs possibly incompletely blocking the androgen receptor in the brain.[14][15]

Similarly to in men, bicalutamide has been associated with minimal or no sexual dysfunction in women.[16] A phase III clinical study of 50 mg/day bicalutamide in conjunction with a combined oral contraceptive in women with severe hirsutism due to polycystic ovary syndrome (PCOS) carefully assessed the side effect of decreased libido and found that the incidence with bicalutamide did not differ from the control group.[16] Minimal rates of reduced sex drive have also been associated with the related NSAA flutamide.[17][18] These findings are in accordance with the fact that women with complete androgen insensitivity syndrome (CAIS) show normal sexual function in spite of complete loss of androgen receptor (AR) signaling.[19] They are also in accordance with a variety of findings concerning testosterone levels and sexual function in premenopausal women, in which no change in parameters of sexual function, including libido, have been observed in association with increases or decreases in testosterone levels.[19] It appears that testosterone levels within the normal physiological range are not importantly involved in sexual desire or function in women.[20]

Psychiatric conditions

[edit]

At 5.3 years follow-up, the incidence of depression was 5.5% for bicalutamide monotherapy relative to 3.0% for placebo in the EPC trial, and the incidence of asthenia (weakness or fatigue) was 10.2% for bicalutamide monotherapy relative to 5.1% for placebo.[21] Rarely, bicalutamide has been associated with hallucinations.[22] This is thought to be secondary to AR antagonism.[22]

Breasts and reproductive system

[edit]
Bicalutamide monotherapy and breast side effects in dose-ranging studies in men
Study N Dosage Gynecomastia Breast tenderness Ref
Tyrrell et al. (1998)a 386 10 mg/day 9% 11% [23]
30 mg/day 26% 42%
50 mg/day 36% 48%
100 mg/day 79% 86%
150 mg/day 78% 89%
200 mg/day 79% 79%
Kennealey & Furr (1991)b 210 10 mg/day 29% 38% [24]
30 mg/day 60% 64%
50 mg/day 52% 60%
Zanardi et al. (2006)c 66 0 mg/week (controls) 0% 0% [25][26][27]
50 mg/week (~7 mg/day) 44% 32%
100 mg/week (~14 mg/day) 50% 64%
Footnotes: a = Testosterone levels increased to ~460–610 ng/dL and estradiol levels to ~32–51 pg/mL. b = Testosterone levels increased to ~505–715 ng/dL and estradiol levels to ~32–53 pg/mL. c = Testosterone levels increased to ~540–600 ng/dL and estradiol levels to ~29–34 pg/mL.

Breast changes

[edit]
Gynecomastia in a 60-year-old man treated with 150 mg/day bicalutamide for prostate cancer.[28]

The most common side effects of bicalutamide monotherapy in men are breast pain/tenderness and gynecomastia.[11] These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy,[29] but gynecomastia is generally reported to occur in 70 to 80% of patients.[30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide monotherapy.[8][9]

Rates of gynecomastia with bicalutamide monotherapy and monotherapy with other NSAA varies significantly across different trials, in reviews ranging from 38 to 85% with bicalutamide, 21 to 80% with flutamide, and 50 to 79% with nilutamide.[31][32] This variation is presumably related to factors like duration of therapy, differing patient characteristics, and the specific methods of collection of adverse-event data.[32][23] One review noted that rates of breast side effects were much lower with open questioning (23–26% for gynecomastia and 26–31% for breast tenderness at 50–150 mg/day bicalutamide) as opposed to direct questioning in studies of bicalutamide monotherapy for prostate cancer.[23]

Gynecomastia associated with NSAA monotherapy usually develops within the first 6 to 9 months following initiation of treatment.[28][33][34] In one study, 89% of those who developed gynecomastia and 98% of those who developed breast pain did so within the first 6 months.[33] Of those who developed gynecomastia, around 55% did so in the first 3 months, around 35% between 3 and 6 months, and 10% after more than 6 months.[33] For breast pain, rates were around 75% in the first 3 months, 25% between 3 and 6 months, and less than 5% after more than 6 months.[33] In the EPC programme, 85% who developed breast pain did so in the first 6 months and 80% who developed gynecomastia did so in the first 9 months.[34]

In more than 90% of affected men, bicalutamide-related breast changes are mild-to-moderate in severity.[9][35][34] It is only rarely and in severe and extreme cases of gynecomastia that the proportions of the male breasts become so marked that they are comparable to those of women.[36] In addition, bicalutamide-associated breast changes improve or resolve in most men upon discontinuation of therapy.[9] In the EPC trial, 16.8% of bicalutamide patients relative to 0.7% of controls withdrew from the study due to breast pain and/or gynecomastia.[35][34] Gynecomastia and breast pain improved or resolved upon discontinuation in 70 and 90% of patients, respectively.[34] Resolution of breast symptoms was dependent on duration of bicalutamide therapy, with resolution rates ranging from 29% with >18 months of treatment to 64% for <6 months of treatment.[34]

Gynecomastia and breast pain/tenderness with NSAA monotherapy is due to increased estradiol levels and unopposed estrogen action in the breasts due to androgen receptor blockade (as androgens inhibit the effects of estrogens in the breasts).[32]

The incidence and severity of gynecomastia are reportedly slightly higher with estrogens (e.g., diethylstilbestrol) (40–80%) than with NSAAs like bicalutamide (40–70%) in the treatment of men with prostate cancer.[37][31]

Management of breast changes

[edit]
Severe gynecomastia with 150 mg/day bicalutamide monotherapy in a 64-year-old man with prostate cancer. Before (left) and after (right) surgical breast reduction.[38]

Tamoxifen, a selective estrogen receptor modulator (SERM) with antiestrogenic actions in breast tissue and estrogenic actions in bone, has been found to be highly effective in preventing and reversing bicalutamide-induced gynecomastia in men.[39][40] Moreover, in contrast to GnRH analogues (which also alleviate bicalutamide-induced gynecomastia), tamoxifen poses minimal risk of accelerated bone loss and osteoporosis.[39][40] For reasons that are unclear, anastrozole, an aromatase inhibitor (or an inhibitor of estrogen biosynthesis), has been found to be much less effective in comparison to tamoxifen for treating bicalutamide-induced gynecomastia.[39][40] A 2015 systematic review of NSAA-induced gynecomastia and breast tenderness concluded that tamoxifen (10–20 mg/day) and radiotherapy could effectively manage the side effect without relevant adverse effects, though with tamoxifen showing superior effectiveness.[41] A 2019 network meta-analysis likewise concluded that tamoxifen was more effective than radiotherapy or anastrozole for preventing bicalutamide-induced gynecomastia.[42] Surgical breast reduction may also be employed to correct bicalutamide-induced gynecomastia.[31]

Tamoxifen doses and rates of bicalutamide-induced breast symptoms in men
Follow-up
timepoint		 Tamoxifen dosage
Placebo 1 mg/day 2.5 mg/day 5 mg/day 10 mg/day 20 mg/day
0 months
–
6 months 98% 90% 80% 54% 22% 10%
12 months 99% 95% 84% 56% 38% 19%
Notes: Prevention of breast symptoms—specifically gynecomastia and breast pain—induced by 150 mg/day bicalutamide monotherapy with tamoxifen in 282 men with prostate cancer. Bicalutamide and tamoxifen were initiated at the same time (0 months). Estradiol levels were in the range of about 22 to 47 pg/mL in the treated group.[43] Sources: [44][43]

Male breast cancer

[edit]

A case report of male breast cancer subsequent to bicalutamide-induced gynecomastia has been published.[45] According to the authors, "this is the second confirmed case of breast cancer in association with bicalutamide-induced gynaecomastia (correspondence AstraZeneca)."[45] It is notable, however, that gynecomastia does not seem to increase the risk of breast cancer in men.[45][46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%,[47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years),[10][48] and millions of men have been treated with bicalutamide for prostate cancer,[49] all of which are potentially in support of the notion of chance co-occurrences.[45] In accordance, the authors concluded that "causality cannot be established" and that it was "probable that the association is entirely coincidental and sporadic."[45]

Lower reproductive system

[edit]

Bicalutamide reduces the size of the prostate gland and seminal vesicles,[50] though not of the testes.[51] Slightly but significantly reduced penile length is also a recognized adverse effect of ADT.[52][53] Reversible hypospermia or aspermia (that is, reduced or absent semen/ejaculate production) may occur.[54][55] However, bicalutamide does not appear to adversely affect spermatogenesis, and thus may not necessarily abolish the capacity/potential for fertility in men.[51][56] Due to the induction of chronic overproduction of LH and testosterone, there was concern that long-term bicalutamide monotherapy might induce Leydig cell hyperplasia and tumors (usually benign),[57] but clinical studies indicate that Leydig cell hyperplasia does not occur to a clinically important extent.[58][56][59]

Male birth defects

[edit]

Because bicalutamide blocks the AR, like all antiandrogens, it can interfere with the androgen-mediated sexual differentiation of the genitalia (and brain) during prenatal development.[60][61][62][63] In pregnant rats given bicalutamide at a dosage of 10 mg/kg/day (resulting in circulating drug levels approximately equivalent to two-thirds of human therapeutic concentrations) and above, feminization of male offspring, such as reduced anogenital distance and hypospadias, as well as impotence, were observed.[64] No other teratogenic effects were observed in rats or rabbits receiving up to very high dosages of bicalutamide (that corresponded to up to approximately two times human therapeutic levels), and no teratogenic effects of any sort were observed in female rat offspring at any dosage.[64] As such, bicalutamide is a selective reproductive teratogen in males, and may have the potential to produce undervirilization/sexually ambiguous genitalia in male fetuses.[60][61] Due to its teratogenic capacity, contraception should be used in women taking bicalutamide who are fertile and sexually active.[65]

Skin, fat, and bone

[edit]

Skin changes

[edit]

Antiandrogen therapy and estrogen therapy are known to produce demasculinizing and feminizing effects in the skin and on hair follicle distribution in people assigned male at birth.[66] Androgens are involved in regulation of the skin (e.g., sebum production), and antiandrogens are known to be associated with skin changes.[58] Skin-related side effects, which included dry skin, itching, and rash, were reported at a rate of 2% in both monotherapy and CAB clinical studies of bicalutamide in men.[58]

Sensitivity to light

[edit]

A few cases of photosensitivity (hypersensitivity to ultraviolet light-induced skin redness and/or lesions) associated with bicalutamide have been reported.[67][68][69] In one of the cases, bicalutamide was continued due to effectiveness in treating prostate cancer in the patient, and in combination with strict photoprotection (in the form of avoidance/prevention of ultraviolet light exposure). Eventually, the symptoms disappeared and did not recur.[67] Flutamide is also associated with photosensitivity, but much more frequently in comparison to bicalutamide.[67][69]

Fat distribution

[edit]

Antiandrogen therapy and estrogen therapy are known to produce demasculinizing and feminizing effects on fat distribution in people assigned male at birth.[66]

Bone density and fractures

[edit]

Bicalutamide monotherapy preserves bone mineral density in men with prostate cancer relative to surgical or medical castration.[7][70][71][72][73] This is considered to be due to preservation of gonadal estradiol production with bicalutamide monotherapy, in contrast to castration which greatly reduces estradiol levels.[7] The risk of osteoporosis and serious bone fractures with bicalutamide monotherapy appears to be no different than with non-use in men with prostate cancer.[74]

Gastrointestinal system

[edit]

The incidence of diarrhea with bicalutamide monotherapy in the EPC trial was comparable to placebo (6.3% vs. 6.4%, respectively).[9] In phase III studies of bicalutamide monotherapy for LAPC, the rates of diarrhea for bicalutamide and castration were 6.4% and 12.5%, respectively, the rates of constipation were 13.7% and 14.4%, respectively, and the rates of abdominal pain were 10.5% and 5.6%, respectively.[75]

Heart, liver, kidneys, and lungs

[edit]

Cardiovascular system

[edit]
See also: Testosterone and the cardiovascular system

A study of high-dose bicalutamide monotherapy (300–600 mg/day) in 248 men with LAPC or metastatic prostate cancer found that there were no effects of bicalutamide on heart rate, blood pressure, or electrocardiogram parameters.[76][77] At the 5-year follow-up of the study, the incidence of cardiovascular events was low, with no differences between the bicalutamide group and the castration group.[76][77] There were also no differences in the incidences of arrhythmia, myocardial infarction, or other ischemic cardiac or cerebrovascular conditions.[76][77]

In the LPC group of the EPC study, which compared 150 mg/day bicalutamide monotherapy versus placebo/standard care, there were numerically more deaths from heart failure (1.2% vs. 0.6%; 49 vs. 25 patients) in the bicalutamide group.[8][78] This contributed to a trend toward significantly increased mortality due to causes other than prostate cancer in the bicalutamide group.[21][79][80] Cardiovascular morbidity, on the other hand, was similar between the bicalutamide and placebo groups.[8][78] In the NRG/RTOG 9601 trial, bicalutamide monotherapy significantly increased the risk of grade 3 to 5 cardiovascular incidents after a median 13 years of follow-up.[81]

A systematic review and meta-analysis of randomized controlled trials of ADT and risk of cardiovascular death in men with non-metastatic prostate cancer was published in 2011.[82] It assessed ADT in the form of a GnRH agonist or surgical castration alone or in combination with a NSAA and included over 4,000 patients.[82] The meta-analysis found no evidence of increased cardiovascular mortality or overall mortality.[82] Non-prostate cancer mortality was not specifically assessed.[82] A limitation of the meta-analysis was that of the trials included in the meta-analysis, only flutamide was employed and not bicalutamide.[82] Subsequent reviews and meta-analyses, published between 2014 and 2022, have reported positive though inconsistent associations of ADT with cardiovascular complications and death.[83][84][85][86][87][88][89]

A case report in which bicalutamide was described as a probable cause of heart failure in a man with prostate cancer has been published.[90]

Lipid profile

[edit]

Bicalutamide has been found to increase total cholesterol and LDL cholesterol levels in women with polycystic ovary syndrome and hirsutism taking a combined birth control pill.[16][91][92] There was also a non-significant trend toward increased triglyceride levels.[16][91][92] Lipid changes with bicalutamide in men with prostate diseases have also been studied, but no significant changes have been found in studies in this population.[93][72][94] Heightened LDL cholesterol and triglyceride levels are potential risk factors for atherosclerosis or coronary heart disease.[95] Unfavorable blood lipid profile changes have also been seen with other antiandrogens in women, for instance cyproterone acetate[96] and spironolactone,[97][98] and with androgenic medications.[99][100][101]

Coagulation

[edit]

NSAA monotherapy is associated with a greater risk of venous thromboembolism (VTE) than non-use, although not to the same extent as surgical or medical castration or particularly high-dose estrogen therapy.[102][103][104][105][106]

Kidney function

[edit]

Androgens and anabolic steroids, including testosterone, have trophic and anabolic effects in the kidneys.[107][108][109][110] Androgen deprivation therapy, including with GnRH agonists and bicalutamide monotherapy, may increase the risk of kidney failure in men.[111][112][113] A large randomized controlled trial in men with prostate cancer found that the incidence of kidney failure was 1 to 2% in men treated with combined androgen blockade using bicalutamide or flutamide, although this study had no placebo group.[114][115][58] Several preclinical studies are suggestive that bicalutamide may have toxic effects on kidney cells.[116][117][111][118][119][120] This may be secondary to androgen deprivation.[116][117][111][118][119][120] Kidney toxicity with bicalutamide and ADT has yet to be fully assessed clinically.[116][117]

Anemia

[edit]

Androgens including testosterone are known to stimulate erythropoiesis (formation of red blood cells) and increase hematocrit (red blood cell levels).[121][122][123] These effects are mediated by increasing production and secretion of erythropoietin from the kidneys.[122] Erythropoietin in turn stimulates erythropoiesis in hematopoietic tissues such as bone marrow.[124] The high levels of testosterone in males are why hematocrit and hemoglobin levels are higher in men than in women.[125] Due to stimulation of erythropoiesis, anabolic–androgenic steroids (AAS) such as oxymetholone and nandrolone decanoate are effective for and used in the treatment of severe anemia (very low hematocrit).[122][126] High doses or levels of AAS, including testosterone, can cause polycythemia—high red blood cell and/or hemoglobin levels that increase the risk of stroke—as an adverse effect.[121][122] Conversely, whether via castration, NSAA monotherapy, or CAB, decreased erythropoiesis resulting in mild anemia is a common side effect of ADT in men.[58][127][123] The incidence of anemia with bicalutamide either as a monotherapy or with castration was about 7.3 to 7.5% in clinical trials, which was similar to the rate with castration of about 7.1%.[58][123] A decrease of hemoglobin levels of 1 to 2 g/dL after about 6 months of treatment may be observed.[127]

Greater decreases in hemoglobin levels and anemia incidences have been reported with flutamide relative to bicalutamide (e.g., 9.8% anemia rate with flutamide plus a GnRH agonist).[128][58][123] Flutamide has been associated with cases of hemolytic anemia, macrocytic anemia, methemoglobinemia, sulfhemoglobinemia, leukopenia, neutropenia, and thrombocytopenia, whereas such complications may not be associated with bicalutamide.[123][129]

Liver toxicity

[edit]

Bicalutamide can cause adverse liver changes rarely, such as elevated transaminases, jaundice, hepatitis, and liver failure.[130] In the EPC trial, in which bicalutamide monotherapy (150 mg/day) was evaluated for treatment of early prostate cancer in 8,113 men, the incidence of abnormal liver function tests at 3-year median follow-up was 3.4% for bicalutamide plus standard care (n=4,052) and 1.9% for standard care alone (n=4,061).[8][131] However, in a phase 3 clinical trial of bicalutamide (50 mg/day) plus a GnRH agonist versus flutamide (750 mg/day) plus a GnRH agonist for metastatic prostate cancer, the rate of abnormal liver function tests was 7.5% with bicalutamide (n=401) and 11.3% with flutamide (n=407).[132][133][134][123][58] Markedly elevated liver enzymes occurred at rates of 0.5% with bicalutamide and 2.5% with flutamide in this trial, whereas rates of drug discontinuation due to elevated liver enzymes were 1.5% with bicalutamide and 2.0% with flutamide.[58][135] In clinical trials, bicalutamide-induced liver changes have usually been transient and have rarely been severe.[8][58] Bicalutamide was discontinued due to liver changes (manifested as hepatitis or marked increases in liver enzymes) in clinical trials in 0.3% to 1.5% of patients, or approximately 1% overall.[64][8][136][137][135] Aside from men with prostate cancer, liver changes have also been observed in women treated with low doses of bicalutamide (10–50 mg/day) for scalp hair loss.[138] Rates of elevated liver enzymes have ranged from 2.9 to 11.4% in these studies, which spontaneously resolved in some women and necessitated discontinuation of treatment in others.[138][139]

No cases of liver failure or death due to liver toxicity were seen with bicalutamide in the initial clinical development programme for prostate cancer which included over 3,900 men treated with bicalutamide.[58][134][140][141][114] These trials employed bicalutamide alone (as a monotherapy) and in combination with castration at doses ranging from 10 to 450 mg/day (with most patients receiving 50 to 150 mg/day).[134][58] Five cases of jaundice, including one man who died of prostate cancer, chronic renal failure, and jaundice, were recorded in the programme.[58][140][141] Rates of jaundice with bicalutamide in the programme were similar to comparator therapies.[58] No instances of fatal hepatotoxicity occurred with 150 mg/day bicalutamide monotherapy in the SPCG-6Tooltip Scandinavian Prostate Cancer Group 6 substudy of the EPC programme, in which 607 men received bicalutamide.[21] Following the initial clinical development programme of bicalutamide for prostate cancer and the EPC programme, cases of grade 3 to 4 (severe or life-threatening/disabling) adverse liver changes have been reported with bicalutamide in subsequent individual trials of bicalutamide for treatment of various types of cancer.[142][143][144][145]

The risk of liver changes with bicalutamide is considered to be small but significant, and monitoring of liver function is recommended.[8][146] Elevation of transaminases above twice the normal range or jaundice may be an indication that bicalutamide should be discontinued.[147] Liver changes with bicalutamide usually occur within the first 3 to 6 months of treatment, and it is recommended that liver function be monitored regularly for the first 4 months of treatment and periodically thereafter.[64][58] Symptoms that may indicate liver dysfunction include nausea, vomiting, abdominal pain, fatigue, anorexia, "flu-like" symptoms, dark urine, and jaundice.[64]

As of 2022, at least 10 case reports of bicalutamide-associated hepatotoxicity or liver failure, two of which were fatal, have been published in the literature.[148][149][130][150][112][151] The dosages of bicalutamide in the cases ranged from 50 to 150 mg/day and the onsets were all within 6 months of therapy.[149][130][150][112][151] One of the cases onset after only two doses of bicalutamide and may have been more related to prolonged prior exposure to flutamide and CPA.[130][152] Aside from published case reports, hundreds of additional cases of liver complications in people taking bicalutamide exist in the FDA Adverse Event Reporting System (FAERS) database.[153] Similarly, additional cases exist in and have been described in published research for other pharmacovigilance systems, such as the Spanish pharmacovigilance system.[154]

Liver toxicity is considered to be much more rare with bicalutamide than with flutamide, and bicalutamide is also regarded as having a lower risk than nilutamide.[155][156][157] Rates of abnormal liver function tests have varied widely between studies, with reported ranges of 4 to 62% with flutamide and 2 to 33% with nilutamide.[123][158][159] The risk of serious or fatal liver toxicity with flutamide has been estimated to be 3 in 10,000 cases, and other studies suggest an even higher incidence.[32][158] By 1996, 46 cases of severe cholestatic hepatitis associated with flutamide had been reported, with 20 of the cases resulting in death.[160] A 2002 review reported that there were 18 reports of hepatotoxicity associated with CPA in the medical literature, with 6 of the reported cases resulting in death.[160] The review also cited a report of an additional 96 instances of hepatotoxicity that were attributed to CPA, of which 33 resulted in death.[160] However, clinically significant liver toxicity has almost exclusively been associated with high doses of CPA in men with prostate cancer (≥100 mg/day).[161][162][163]

There is no evidence of greater liver function changes with higher doses of bicalutamide, and hence the liver toxicity of bicalutamide is not currently known to be dose-dependent across its clinically used dosage range.[164] Older age, for a variety of reasons, appears to be an important risk factor for drug-induced hepatotoxicity.[165][166] As such, the risk of liver changes with bicalutamide may be lower in younger individuals, for instance women with hirsutism and transgender women.[165][166] However, it has been reported on the basis of very limited evidence that this may not be the case with flutamide.[167]

From a theoretical standpoint (on the basis of structure–activity relationships), it has been suggested that flutamide, bicalutamide, and nilutamide, to varying extents, all have the potential to cause liver toxicity.[168] However, in contrast to flutamide, hydroxyflutamide, and nilutamide, bicalutamide exhibits less or no mitochondrial toxicity and inhibition of enzymes in the electron transport chain such as respiratory complex I (NADH ubiquinone oxidoreductase), and this may be the reason for its lower risk of hepatotoxicity in comparison.[169][170][171][172] The activity difference may be related to the fact that flutamide, hydroxyflutamide, and nilutamide all possess a nitroaromatic group, whereas in bicalutamide, a cyano group is present in place of this nitro group, potentially reducing toxicity.[156][169][172][173] A potential biological target mediating hepatotoxicity with antiandrogens, such as flutamide and cyproterone acetate, is the aryl hydrocarbon receptor.[174][175][176]

Published case reports of bicalutamide-associated liver injury
# Age Sex Dosage Use Onset Outcome Source
1 60 years Male 50 mg/day Prostate cancer 2 days Survived Dawson et al. (1997)
2 79 years Male 80 mg/day Prostate cancer 1.5 months Survived Ikemoto et al. (2000)
3 59 years Male 50 mg/day Prostate cancer 4 days Death O'Bryant et al. (2008)
4 61 years Male 50 mg/day Prostate cancer 3.5 months Death Castro Beza et al. (2008)
5 81 years Male 150 mg/day Prostate cancer 3 weeks Survived Hussain et al. (2014)
6 62 years Male 100 mg/day Prostate cancer 4.5 months Survived Yun et al. (2016)
7 67 years Male 150 mg/day Prostate cancer 3 weeks Survived Gretarsdottir et al. (2018)
8 79 years Male Unknown Prostate cancer 15 days Survived Saito (2020)
9 17 years Trans female Unknown Gender-affirming hormone therapy 1 year Survived Reed (2023)
10 17 years Trans female 50 mg/day Gender-affirming hormone therapy 3 months Survived Wilde et al. (2023)
Notes: Additional cases of bicalutamide-associated adverse liver changes have been reported. These include 11 cases in a 2006 Spanish pharmacovigilance system report (including 1 case of hepatitis, 2 cases of cholestatic hepatitis, 1 case of jaundice, 4 cases of elevated liver enzymes, and 1 case of elevated bilirubin; no deaths) and a number of cases in the FDA Adverse Event Reporting System (FAERS). Also 5 cases of jaundice were reported out of ~3,700 men in clinical trials but no cases of liver failure or of liver-toxicity-related death clearly attributable to bicalutamide were observed. Sources: Main: [177][178]

Lung toxicity

[edit]

Case reports of interstitial pneumonitis associated with bicalutamide treatment have been published in the medical literature.[179][180][181][182] Hundreds of additional cases of interstitial lung disease in people taking bicalutamide exist in the FDA Adverse Event Reporting System (FAERS) database.[153] Interstitial pneumonitis can progress to pulmonary fibrosis and can be fatal. Interstitial pneumonitis with bicalutamide is said to be a very rare event.[183] The risk is much lower than that with nilutamide (which has an incidence rate of 0.5–2% of patients).[184]: 81 [180][185] In a large cohort of prostate cancer patients, the incidence of interstitial pneumonitis with NSAAs was 0.77% for nilutamide, 0.04% (4 per 10,000) for flutamide, and 0.01% (1 per 10,000) for bicalutamide.[3] An assessment done prior to the publication of the aforementioned study estimated the rates of pulmonary toxicity with flutamide, bicalutamide, and nilutamide as 1 case, 5 cases, and 303 cases per million, respectively.[186] Strong safety signals of bicalutamide with interstitial lung disease have been observed in pharmacovigilance databases such as the FAERS and Japanese Adverse Drug Event Report (JADER) databases (e.g., RORTooltip reporting odds ratio = 9.2, 95% CITooltip confidence interval = 7.9–10.6; ROR = 8.2, 95% CI = 6.0–11.2).[187][188][189] Similar safety signals have been observed for certain other antiandrogens, like nilutamide and flutamide.[187][189] In addition to interstitial pneumonitis, there is a smaller number of published case reports of eosinophilic lung disease associated with bicalutamide.[190][191] Side effects associated with the rare lung toxicity of bicalutamide may include dyspnea (difficult breathing or shortness of breath), cough, and pharyngitis (inflammation of the pharynx, resulting in sore throat).[192]

Published case reports of bicalutamide-associated lung toxicity
# Age Sex Dosage Onset Type of injury Outcome Ref
1 69 years Male 200 mg/day 6 months Eosinophilic lung disease Recovered Wong et al. (1998)
2 ~76 years Male 200 mg/day 8 months Interstitial pneumonitis Recovered McCaffrey & Scher (1998)
3 ~82 years Male 80 mg/day 4 weeks Interstitial pneumonitis Recovered Shioi et al. (2003)
4 ~72 years Male 80 mg/day 2.5 months Interstitial pneumonitis Recovered, then deatha Shioi et al. (2005)
5 84 years Male ? 8 months Interstitial pneumonitis Recovered Kobayashi et al. (2006)
6 76 years Male ? ? Interstitial pneumonitis ? Gifford & DeLong (2008)
7 85 years Male ? 4 months Interstitial pneumonitis Death Kawahara et al. (2009)
8 78 years Male 80 mg/day 8 months Interstitial pneumonitis Recovered Masago et al. (2011)
9 77 years Male ? 7 months Interstitial pneumonitis Death Song et al. (2014)
10 77 years Male >50 mg/day ~12 months Interstitial pneumonitis Death Molina Mancero et al. (2016)
11 79 years Male ? 1 month Interstitial pneumonitis Death Polatoglu et al. (2017)
12 66 years Male ? ? Interstitial pneumonitis Recovered Kim et al. (2018)
13 66 years Male ? ? Interstitial pneumonitis Recovered Derichs et al. (2018)
14 86 years Male 150 mg/day 6 years Eosinophilic pneumonitis Recovered Umeojiako & James (2019)
15 75 years Male ? 2 weeks Interstitial pneumonitis Death Maeda et al. (2019)
16 79 years Male ? 1.5 months Interstitial pneumonitis Recovered Saito (2020)
17 66 years Male 50 mg/day 6 months Interstitial pneumonitis Recovered Smith & Antonarakis (2020)
Footnotes: a = Died of pneumothorax followed by spontaneous rupture of bulla induced by previous interstitial pneumonitis 14 months after discontinuation of bicalutamide and recovery from interstitial pneumonitis. Notes: Twelve additional cases of bicalutamide-associated interstitial pneumonitis, three of which resulted in death, were observed in an 87,000-patient cohort from MedWatch (U.S.Tooltip United States FDATooltip Food and Drug Administration passive adverse-event reporting database) between 1998 and 2000 (0.01% incidence). The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks). Cases of interstitial pneumonitis have also been reported in association with flutamide, nilutamide, and gonadotropin-releasing hormone (GnRH) agonists.

Risk of death

[edit]

In men with early prostate cancer, bicalutamide has been shown to increase the likelihood of death due to causes other than prostate cancer.[81] This was shown in the SPCG-6Tooltip Scandinavian Prostate Cancer Group 6 substudy (n=1218) of the EPC programme, in which overall survival was significantly worse in the 150 mg/day bicalutamide monotherapy group compared to the placebo/standard care group (HRTooltip hazard ratio = 1.47; 95% CITooltip confidence interval = 1.06–2.03).[81] There was also a near-significant trend toward increased overall mortality in the combined programme (n=8113) (HR = 1.16; 95% CI = 0.99–1.37; p=0.07).[81] At 5.4 years of follow-up for the EPC programme, the overall incidence of death was 25.2% in the bicalutamide group and 20.5% in the placebo/standard care group.[21][79][80] This was because more bicalutamide than placebo/standard care recipients had died due to causes unrelated to prostate cancer (16.8% vs. 9.5% at 5.4-year follow-up; 10.2% vs. 9.2% at 7.4-year follow-up).[21][80][8] Bicalutamide reduced mortality due to prostate cancer, but this was not sufficient to overcome the increase in mortality due to non-prostate-cancer causes.[21][79][80] Other trials, such as NRG/RTOG 9601, have also reported increased mortality with bicalutamide.[81] Consequent to the EPC programme findings, authorization of bicalutamide for the treatment of LPC was revoked, and use of bicalutamide for this indication was discontinued.[8][80][79][193] Bicalutamide continues to be authorized and used in the treatment of LAPC and mPC, where the benefits of bicalutamide against prostate cancer outweigh any influence on non-prostate-cancer mortality.[8]

The reasons for the increased overall mortality with bicalutamide seen in the EPC programme have not been fully elucidated.[30] In any case, at 7.4-year follow-up, there were numerically more deaths from heart failure (1.2% vs. 0.6%) and gastrointestinal cancer (1.3% vs. 0.9%) in the bicalutamide group relative to placebo/standard care recipients.[8][78][194] It has been said that there was no consistent pattern suggestive of drug-related toxicity for bicalutamide and that the causes were likely a consequence of androgen deprivation:[195][196][8][78][197]

The increased number of deaths in patients with localized disease receiving bicalutamide was meticulously investigated and they appeared to be due to a number of small imbalances rather than a specific cause. In addition, no direct toxic effect on any organ system could be identified. From this it may be speculated that the excess deaths in patients who are at low risk from prostate cancer mortality reflect the impact of endocrine therapy (rather than bicalutamide in particular). [...] The increased number of non-prostate cancer deaths in the early castration therapy arm [(via orchiectomy or GnRH monotherapy)] in the [Medical Research Council] study suggests that the trend towards an increased number of deaths in patients with localized disease in the present study is a reflection of early endocrine therapy as a concept rather than a bicalutamide-related phenomenon.[195]

The increased number of deaths in bicalutamide-treated patients under watchful waiting with localized disease appears to be due to the accumulation of several small imbalances in various causes of death rather than an identifiable specific cause. However, an indirect effect from androgen receptor blockade, or some other unknown hormonally mediated effect, can neither be confirmed nor refuted with current data.[196]

Low testosterone levels in men have been associated in epidemiological studies with cardiovascular disease as well as with a variety of other disease states.[198] These include hypertension, hypercholesterolemia, diabetes, obesity, Alzheimer's disease, osteoporosis, and frailty.[198] In any case, although bicalutamide monotherapy blocks the actions of androgens, it simultaneously preserves relatively high estradiol levels in men.[199][200][136] This would potentially be expected to reduce or offset many of the risks of sex hormone deprivation.[201][202][203][204] Yet increased mortality has still been seen with bicalutamide monotherapy in men in clinical trials.[81][8]

Modification of side effects by castration

[edit]

Combination of bicalutamide with medical (i.e., a GnRH analogue) or surgical castration modifies the side-effect profile of bicalutamide. Some of its side effects, including breast pain/tenderness and gynecomastia, are far less likely to occur when the drug is combined with a GnRH analogue,[205] while certain other side effects, including hot flashes, depression, fatigue, and sexual dysfunction,[206] occur much more frequently in combination with a GnRH analogue.[12][207][208] It is thought that this is due to the suppression of estrogen levels (in addition to androgen levels) by GnRH analogues, as estrogens may compensate for various negative central effects of androgen deprivation.[12] If bicalutamide is combined with a GnRH analogue or surgical castration, the elevation of androgen and estrogen levels in men caused by bicalutamide will be prevented and the side effects of excessive estrogens, namely gynecomastia, will be reduced.[205] However, due to the loss of estrogen, bone loss will accelerate and the risk of osteoporosis developing with long-term therapy will increase.[209]

References

[edit]
  1. ^ Mcleod DG (September 2002). "Emerging role of adjuvant hormonal therapy". Urology. 60 (3 Suppl 1): 13–20, discussion 21. doi:10.1016/S0090-4295(02)01562-5. PMID 12231039.
  2. ^ "Bicalutamide" (PDF). Richmond Hill, Ontario: Nu-Pharm Inc. October 2009.
  3. ^ a b Bennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Annals of Internal Medicine. 137 (7): 625. doi:10.7326/0003-4819-137-7-200210010-00029. PMID 12353966. An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.
  4. ^ Molina Mancero G, Picón X, Di Tullio F, Ernst G, Dezanzo P, Salvado A, Chertcoff JF (October 2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case]. Revista médica de Chile (in Spanish). 144 (10): 1356–1359. doi:10.4067/S0034-98872016001000017. PMID 28074993.
  5. ^ Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide - case report and review of the literature". Photodermatology, Photoimmunology & Photomedicine. 32 (3): 161–164. doi:10.1111/phpp.12230. PMID 26663090. S2CID 2761388.
  6. ^ Gretarsdottir HM, Bjornsdottir E, Bjornsson ES (2018). "Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect". Case Reports in Gastroenterology. 12 (2): 266–270. doi:10.1159/000485175. ISSN 1662-0631. S2CID 81661015.
  7. ^ a b c Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU International. 91 (5): 455–461. doi:10.1046/j.1464-410X.2003.04026.x. PMID 12603397. S2CID 8639102.
  8. ^ a b c d e f g h i j k l m n o p q r Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer" (PDF). Drugs. 66 (6): 837–50. doi:10.2165/00003495-200666060-00007. PMID 16706554. S2CID 46966712. Archived (PDF) from the original on 28 August 2016.
  9. ^ a b c d e f g Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU International. 91 (5): 455–61. doi:10.1046/j.1464-410X.2003.04026.x. PMID 12603397. S2CID 8639102.
  10. ^ a b Rahman HP, Hofland J, Foster PA (2016). "In touch with your feminine side: how oestrogen metabolism impacts prostate cancer" (PDF). Endocrine-Related Cancer. 23 (6): R249–66. doi:10.1530/ERC-16-0118. PMID 27194038. Prostate cancer primarily affects the elderly with 99.9% of patients diagnosed over the age of 50 and the mean age at diagnosis being 73 (Parkin, et al. 1997).
  11. ^ a b Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 150–152. ISBN 978-0-08-093292-7. In contrast [to flutamide and nilutamide], no specific non-pharmacological complications have been linked to bicalutamide, while diarrhea and abnormal liver function occur less often than with flutamide.
  12. ^ a b c Iversen P, Melezinek I, Schmidt A (January 2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". BJU International. 87 (1): 47–56. doi:10.1046/j.1464-410x.2001.00988.x. PMID 11121992. S2CID 28215804.
  13. ^ Migliari R, Muscas G, Usai E (August 1992). "Effect of Casodex on sleep-related erections in patients with advanced prostate cancer". J. Urol. 148 (2 Pt 1): 338–41. doi:10.1016/S0022-5347(17)36588-6. PMID 1378907.
  14. ^ Iversen P, Melezinek I, Schmidt A (January 2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". BJU Int. 87 (1): 47–56. doi:10.1046/j.1464-410x.2001.00988.x. PMID 11121992. S2CID 28215804.
  15. ^ Mahler C, Verhelst J, Denis L (May 1998). "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer". Clin Pharmacokinet. 34 (5): 405–17. doi:10.2165/00003088-199834050-00005. PMID 9592622. S2CID 25200595. If used in monotherapy, libido and potency are largely preserved. Although the mechanisms to explain this are not completely understood, it seems that at the central level pure antiandrogens are unable to completely inhibit the effect of the increased amount of androgens.
  16. ^ a b c d Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A (March 2018). "Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial". J. Clin. Endocrinol. Metab. 103 (3): 824–838. doi:10.1210/jc.2017-01186. PMID 29211888.
  17. ^ Paradisi R, Fabbri R, Porcu E, Battaglia C, Seracchioli R, Venturoli S (October 2011). "Retrospective, observational study on the effects and tolerability of flutamide in a large population of patients with acne and seborrhea over a 15-year period". Gynecol. Endocrinol. 27 (10): 823–9. doi:10.3109/09513590.2010.526664. PMID 21117864. S2CID 20250916. Among the slight and temporary adverse events [of flutamide], most frequently reported and not requesting treatment discontinuation were headache (7.8%), respiratory tract disorders (7.0%), nausea and/or vomiting (4.0%), diarrhea (4.0%), dry skin (9.5%), and reduction of libido (4.5%).
  18. ^ Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, Gualerzi B, Porcu E, Seracchioli R (2001). "Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism". Horm. Res. 56 (1–2): 25–31. doi:10.1159/000048086 (inactive 2024-11-09). PMID 11815724. S2CID 46782286.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
  19. ^ a b Reed BG, Bou Nemer L, Carr BR (2016). "Has testosterone passed the test in premenopausal women with low libido? A systematic review". Int J Women's Health. 8: 599–607. doi:10.2147/IJWH.S116212. PMC 5066846. PMID 27785108.
  20. ^ Cappelletti M, Wallen K (February 2016). "Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens". Horm Behav. 78: 178–93. doi:10.1016/j.yhbeh.2015.11.003. PMC 4720522. PMID 26589379.
  21. ^ a b c d e f Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K (November 2004). "Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6". The Journal of Urology. 172 (5 Pt 1): 1871–6. doi:10.1097/01.ju.0000139719.99825.54. PMID 15540741. Abnormal liver function tests, assessed by adverse events or as clinically relevant changes in liver function parameters, were infrequent, transient and rarely severe with bicalutamide. There were no reports of bicalutamide induced fatal hepatotoxicity.
  22. ^ a b Turkkan G, Dogan C, Tek B (November 2019). "Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report". J Oncol Pharm Pract. 26 (4): 1029–1031. doi:10.1177/1078155219886918. PMID 31707924. S2CID 207947815.
  23. ^ a b c Tyrrell CJ, Denis L, Newling D, Soloway M, Channer K, Cockshott ID (1998). "Casodex 10-200 mg daily, used as monotherapy for the treatment of patients with advanced prostate cancer. An overview of the efficacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group". Eur. Urol. 33 (1): 39–53. doi:10.1159/000019526. PMID 9471040. S2CID 71758492. The relatively high incidence of breast tenderness and gynaecomastia seen in these studies is likely to be a consequence of the direct questioning which was used to elicit these adverse events. Previously published studies using a dose of Casodex of 50, 100 and 150 mg daily [23-26] where these events were elicited by open questioning during Casodex therapy, found the incidence of gynaecomastia (23-26%) and breast tenderness (26-31 %) to be much lower.
  24. ^ Kennealey GT, Furr BJ (February 1991). "Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma". Urol. Clin. North Am. 18 (1): 99–110. doi:10.1016/S0094-0143(21)01397-5. PMID 1992575.
  25. ^ Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Branchi D, Argusti A, Campodonico F, Turbino L, Mori M, Decensi A (1 December 2006). "A biomarker trial of intermittent, low-dose bicalutamide in subjects at high risk for prostate cancer: Updated results". Cancer Epidemiol Biomarkers Prev. 15 (12 Supplement): A145. Testosterone (T), LH, E2 and SHBG levels increased on Bic, although only T changes on both doses and LH changes on Bic 100 mg were significantly different to controls (p<0.001). Changes in circulating hormones and biomarkers were evident after 3 months, and persisted through the 6th month of treatment. No change in circulating hormones or biomarkers was observed in the control group. [...] Treatment was well tolerated, although breast pain was recorded in 0/19 (0%), 8/25 (32%) and 14/22 (64%), and gynecomastia in 0/19 (0%), 11/25 (44%) and 11/22 (50%) of subjects on no treatment, Bic 50 or 100 mg, respectively.
  26. ^ Zanardi, S.; Puntoni, M.; Maffezzini, M.; Bandelloni, R.; Mori, M.; Argusti, A.; Campodonico, F.; Turbino, L.; Branchi, D.; Montironi, R.; Decensi, A. (2009). "Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies". Cancer Prevention Research. 2 (4): 377–384. doi:10.1158/1940-6207.CAPR-08-0205. ISSN 1940-6207. PMID 19336728.
  27. ^ Decensi A, Zanardi S, Puntoni M, Bandelloni R, Branchi D, Argusti A, Campodonico F, Turbino L, Mori M, Maffezzini M (20 June 2007). "Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy". Journal of Clinical Oncology. 25 (18_suppl): 1500. doi:10.1200/jco.2007.25.18_suppl.1500. T, LH, estradiol and SHBG increased on Bic by 50–60%. [...] Treatment was well tolerated, mild (G1) breast pain and gynecomastia being recorded in 40% of treated subjects.
  28. ^ a b Michalopoulos NV, Keshtgar MR (2012). "Images in clinical medicine. Gynecomastia induced by prostate-cancer treatment". The New England Journal of Medicine. 367 (15): 1449. doi:10.1056/NEJMicm1209166. PMID 23050528. Gynecomastia occurs in up to 80% of patients who receive nonsteroidal antiandrogens (eg, bicalutamide, flutamide, or nilutamide), usually within the first 6 to 9 months after the initiation of treatment.
  29. ^ Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (2007). "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study". European Urology. 52 (1): 106–14. doi:10.1016/j.eururo.2007.01.031. PMID 17270340.
  30. ^ a b Wirth MP, Hakenberg OW, Froehner M (February 2007). "Antiandrogens in the treatment of prostate cancer". European Urology. 51 (2): 306–13, discussion 314. doi:10.1016/j.eururo.2006.08.043. PMID 17007995.
  31. ^ a b c Di Lorenzo G, Autorino R, Perdonà S, De Placido S (2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". Lancet Oncol. 6 (12): 972–9. doi:10.1016/S1470-2045(05)70464-2. PMID 16321765.
  32. ^ a b c d Fourcade, R.-O.; McLeod, D. (March 2004). "Tolerability of Antiandrogens in the Treatment of Prostate Cancer". UroOncology. 4 (1): 5–13. doi:10.1080/1561095042000191655. ISSN 1561-0950. The risk of fatal or serious hepatic toxicity associated with flutamide was estimated to be 3 of 10,000 based on cases reported to the Food and Drug Administration in the USA [59], although others suggest that the incidence may be higher than this [57].
  33. ^ a b c d Van Poppel H, Tyrrell CJ, Haustermans K, Cangh PV, Keuppens F, Colombeau P, Morris T, Garside L (May 2005). "Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer". Eur Urol. 47 (5): 587–92. doi:10.1016/j.eururo.2004.12.003. PMID 15826748. 3.2. Incidence, time to onset and intensity of symptoms. Of the 51 patients, 37 (72.5%) experienced gynaecomastia and 41 (80.4%) experienced breast pain within the 12 months following initiation of bicalutamide 150 mg. Time to onset of these symptoms is illustrated in Fig. 1. Generally, gynaecomastia and breast pain were reported within the first 6 months of treatment (89.2% [33/37] and 97.6% [40/41], respectively).
  34. ^ a b c d e f Carswell CI, Figgitt DP (2002). "Bicalutamide: in early-stage prostate cancer". Drugs. 62 (17): 2471–79, discussion 2480–1. doi:10.2165/00003495-200262170-00006. PMID 12421104. S2CID 195690919.
  35. ^ a b Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". Drugs. 66 (6): 837–50. doi:10.2165/00003495-200666060-00007. PMID 16706554. S2CID 46966712.
  36. ^ Brown JS, Rubenfeld S (1974). "Irradiation in preventing gynecomastia induced by estrogens". Urology. 3 (1): 51–3. doi:10.1016/s0090-4295(74)80060-9. PMID 4812899. Infrequently, the breast hypertrophy can become so marked that it attains proportions comparable to that in female breasts.
  37. ^ Deepinder F, Braunstein GD (2012). "Drug-induced gynecomastia: an evidence-based review". Expert Opinion on Drug Safety. 11 (5): 779–95. doi:10.1517/14740338.2012.712109. PMID 22862307. S2CID 22938364. Treatment with estrogen has the highest incidence of gynecomastia, at 40 – 80%, anti-androgens, including flutamide, bicalutamide and nilutamide, are next, with a 40 – 70% incidence, followed by GnRH analogs (goserelin, leuprorelin) and combined androgen deprivation, both with incidences of 13% each.
  38. ^ Nakabayashi M, Bartlett RA, Oh WK (2006). "Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer". Journal of Clinical Oncology. 24 (18): 2958–9. doi:10.1200/JCO.2005.03.8505. PMID 16782932.
  39. ^ a b c Saltzstein D, Sieber P, Morris T, Gallo J (2005). "Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole". Prostate Cancer and Prostatic Diseases. 8 (1): 75–83. doi:10.1038/sj.pcan.4500782. PMID 15685254.
  40. ^ a b c Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F (February 2005). "Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer". Journal of Clinical Oncology. 23 (4): 808–15. doi:10.1200/JCO.2005.12.013. PMID 15681525.
  41. ^ Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, Selvaggi G (2015). "Gynecomastia in Patients with Prostate Cancer: A Systematic Review". PLOS ONE. 10 (8): e0136094. Bibcode:2015PLoSO..1036094F. doi:10.1371/journal.pone.0136094. PMC 4550398. PMID 26308532.
  42. ^ Shaikh, P.; Bakalov, V.; Vargo, A.; Alite, F.; Wu, M.J.; Kamali, K.; Jacobson, G. (2019). "Prophylaxis for bicalutamide-induced gynecomastia: a network meta-analysis". Value in Health. 22: S437–S438. doi:10.1016/j.jval.2019.09.212. ISSN 1098-3015.
  43. ^ a b Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S (July 2007). "Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study". Eur. Urol. 52 (1): 106–14. doi:10.1016/j.eururo.2007.01.031. PMID 17270340.
  44. ^ Fentiman IS (January 2018). "Managing Male Mammary Maladies". Eur J Breast Health. 14 (1): 5–9. doi:10.5152/ejbh.2017.3841. PMC 5758064. PMID 29322112.
  45. ^ a b c d e Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 155–. ISBN 978-0-08-093292-7.
  46. ^ Cuhaci N, Polat SB, Evranos B, Ersoy R, Cakir B (March 2014). "Gynecomastia: Clinical evaluation and management". Indian Journal of Endocrinology and Metabolism. 18 (2): 150–8. doi:10.4103/2230-8210.129104. PMC 3987263. PMID 24741509.
  47. ^ Nussbaum RL, McInnes RR, Willard HF (21 May 2015). Thompson & Thompson Genetics in Medicine. Elsevier Health Sciences. pp. 319–. ISBN 978-1-4377-0696-3.
  48. ^ Christopher Li (11 November 2009). Breast Cancer Epidemiology. Springer Science & Business Media. pp. 261–. ISBN 978-1-4419-0685-4.
  49. ^ Chang S (10 March 2010), Bicalutamide BPCA Drug Use Review in the Pediatric Population (PDF), U.S. Department of Health and Human Service, archived (PDF) from the original on 24 October 2016, retrieved 20 July 2016
  50. ^ Furr BJ, Tucker H (January 1996). "The preclinical development of bicalutamide: pharmacodynamics and mechanism of action". Urology. 47 (1A Suppl): 13–25, discussion 29–32. doi:10.1016/S0090-4295(96)80003-3. PMID 8560673.
  51. ^ a b Morgante E, Gradini R, Realacci M, Sale P, D'Eramo G, Perrone GA, Cardillo MR, Petrangeli E, Russo M, Di Silverio F (March 2001). "Effects of long-term treatment with the anti-androgen bicalutamide on human testis: an ultrastructural and morphometric study". Histopathology. 38 (3): 195–201. doi:10.1046/j.1365-2559.2001.01077.x. hdl:11573/387981. PMID 11260298. S2CID 36892099.
  52. ^ Higano CS (2012). "Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer". Journal of Clinical Oncology. 30 (30): 3720–5. doi:10.1200/JCO.2012.41.8509. PMID 23008326.
  53. ^ Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR (May 2015). "Adverse effects of androgen deprivation therapy and strategies to mitigate them". European Urology. 67 (5): 825–36. doi:10.1016/j.eururo.2014.07.010. PMID 25097095.
  54. ^ Mazzola CR, Mulhall JP (March 2012). "Impact of androgen deprivation therapy on sexual function". Asian Journal of Andrology. 14 (2): 198–203. doi:10.1038/aja.2011.106. PMC 3735098. PMID 22231298.
  55. ^ Mulcahy JJ (1 January 2001). Male Sexual Function. Springer Science & Business Media. pp. 3–. ISBN 978-1-59259-098-8. Archived from the original on 20 May 2016.
  56. ^ a b Bjerklund Johansen TE, Majak M, Nesland JM (March 1994). "Testicular histology after treatment with the new antiandrogen Casodex for carcinoma of the prostate. A preliminary report". Scand. J. Urol. Nephrol. 28 (1): 67–70. doi:10.3109/00365599409180473. PMID 8009196.
  57. ^ Scialli AR, Clegg ED (9 June 1992). Reversibility in Testicular Toxicity Assessment. CRC Press. pp. 107–. ISBN 978-0-8493-5980-4.
  58. ^ a b c d e f g h i j k l m n o Kolvenbag GJ, Blackledge GR (January 1996). "Worldwide activity and safety of bicalutamide: a summary review". Urology. 47 (1A Suppl): 70–9, discussion 80–4. doi:10.1016/S0090-4295(96)80012-4. PMID 8560681. [...] In the combination study,9 the incidence of hepatic adverse events was lower in bicalutamide plus LHRH-A group than in the flutamide plus LHRH-A group (6.7% versus 12%; P = 0.07). [...] In the clinical trial program, evaluation of biochemistry assessments showed that increases in the liver function test values for serum glutamic oxaloacetic transaminase (SGOT; aspartate aminotransferase) and serum glutamic pyruvic transaminase (SGPT; alanine aminotransaminase) occurred with greater frequency in the flutamide plus LHRH-A group than in the bicalutamide plus LHRH-A group (49 [12.0%] and 28 [7.0%] patients, respectively). The difference between groups was observed for both test results that were less than twice the upper limit of normal (ULN) and for test results that were greater than two times the ULN. [\n\n] In the combination study, 77 patients (28 [7.0%], bicalutamide plus LHRH-A; 49 [12.0%], flutamide plus LHRH) had at least one liver enzyme test result (SGOT or SGPT) that exceeded twice the ULN. For these patients, there was no clear pattern to distinguish between SGOT versus SGPT changes as drug induced; changes were observed for both enzymes (either alone or together) while patients received study therapy. Of these 77 patients, 52 had an increase in SGOT and/or SGPT levels >2 ✕ ULN on only one occasion. [\n\n] Drug-induced changes were more likely when liver function test values were above the ULN at more than one assessment. This finding was observed more often for flutamide-treated patients than for bicalutamide-treated patients (17 [4.2%] vs 8 [2.0%]). Liver function test values >5 ✕ ULN (SGOT >325 U/L [patients >65 years]; SGPT >265 U/L) after the start of therapy were more frequently observed for patients who received flutamide plus LHRH-A (10 of 407 patients) [2.5%] than patients who received bicalutamide plus LHRH-A (2 of 401 patients) [0.5%].
  59. ^ Jones HB, Betton GR, Bowdler AL, McFarquhar RL, Middleton BJ, Lunglmayr G (1994). "Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy". Urol. Res. 22 (3): 191–5. doi:10.1007/BF00571849. PMID 7992465. S2CID 19540140.
  60. ^ a b Iswaran TJ, Imai M, Betton GR, Siddall RA (May 1997). "An overview of animal toxicology studies with bicalutamide (ICI 176,334)". The Journal of Toxicological Sciences. 22 (2): 75–88. doi:10.2131/jts.22.2_75. PMID 9198005.
  61. ^ a b Smith RE (4 April 2013). Medicinal Chemistry – Fusion of Traditional and Western Medicine. Bentham Science Publishers. pp. 306–. ISBN 978-1-60805-149-6. Archived from the original on 29 May 2016.
  62. ^ Sex Differences in the Human Brain, their underpinnings and implications. Elsevier. 3 December 2010. pp. 44–45. ISBN 978-0-444-53631-0. Archived from the original on 26 May 2016.
  63. ^ Paoletti R (6 December 2012). Chemistry and Brain Development: Proceedings of the Advanced Study Institute on "Chemistry of Brain Development," held in Milan, Italy, September 9–19, 1970. Springer Science & Business Media. pp. 218–. ISBN 978-1-4684-7236-3.
  64. ^ a b c d e "Casodex® (bicalutamide) Tablets" (PDF). FDA. Archived (PDF) from the original on 27 February 2017.
  65. ^ Papadimitriou, Kasiani; Anagnostis, Panagiotis; Goulis, Dimitrios G. (2022). "The challenging role of antiandrogens in the management of polycystic ovary syndrome". Polycystic Ovary Syndrome. Elsevier. pp. 297–314. doi:10.1016/B978-0-12-823045-9.00013-4. ISBN 9780128230459. S2CID 244697776.
  66. ^ a b Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (December 2017). "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline". Endocr Pract. 23 (12): 1437. doi:10.4158/1934-2403-23.12.1437. PMID 29320642. S2CID 3639218.
  67. ^ a b c Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide – case report and review of the literature". Photodermatology, Photoimmunology & Photomedicine. 32 (3): 161–4. doi:10.1111/phpp.12230. PMID 26663090. S2CID 2761388.
  68. ^ Lee K, et al. (2016). "Drug-induced photosensitivity to bicalutamide – case report and review of the literature". Reactions Weekly. 1612 (1): 161–4. doi:10.1007/s40278-016-19790-1. PMID 26663090. S2CID 261402820.
  69. ^ a b Sasada K, Sakabe J, Tamura A, Kasuya A, Shimauchi T, Ito T, Hirakawa S, Tokura Y (2012). "Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum". European Journal of Dermatology. 22 (3): 402–3. doi:10.1684/ejd.2012.1719. PMID 22503957.
  70. ^ Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I (May 2003). "The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study". World J Urol. 21 (1): 37–42. doi:10.1007/s00345-003-0322-7. PMID 12756493. S2CID 13355134.
  71. ^ Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (July 2004). "Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition". J. Clin. Oncol. 22 (13): 2546–53. doi:10.1200/JCO.2004.01.174. PMID 15226323.
  72. ^ a b Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (June 2004). "Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer". J. Urol. 171 (6 Pt 1): 2272–6, quiz 2435. doi:10.1097/01.ju.0000127738.94221.da. PMID 15126801.
  73. ^ Wadhwa VK, Weston R, Parr NJ (June 2011). "Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer". BJU Int. 107 (12): 1923–9. doi:10.1111/j.1464-410X.2010.09726.x. PMID 20950306. S2CID 205543615.
  74. ^ Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J (July 2012). "Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden". Eur. J. Cancer. 48 (11): 1672–81. doi:10.1016/j.ejca.2012.01.035. PMID 22386317.
  75. ^ Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I (2000). "Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup". The Journal of Urology. 164 (5): 1579–82. doi:10.1016/s0022-5347(05)67032-2. PMID 11025708.
  76. ^ a b c Chodak G, Gomella L, Phung de H (September 2007). "Combined androgen blockade in advanced prostate cancer: looking back to move forward". Clin Genitourin Cancer. 5 (6): 371–8. doi:10.3816/CGC.2007.n.019. PMID 17956709.
  77. ^ a b c Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T (September 2006). "Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration". BJU Int. 98 (3): 563–72. doi:10.1111/j.1464-410X.2006.06275.x. PMID 16771791. S2CID 41672303.
  78. ^ a b c d Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE (2012). "Contemporary role of androgen deprivation therapy for prostate cancer". European Urology. 61 (1): 11–25. doi:10.1016/j.eururo.2011.08.026. PMC 3483081. PMID 21871711.
  79. ^ a b c d Bowsher W, Carter A (15 April 2008). Challenges in Prostate Cancer. John Wiley & Sons. pp. 146–. ISBN 978-1-4051-7177-9.
  80. ^ a b c d e Shahani R, Fleshner NE, Zlotta AR (2007). "Pharmacotherapy for prostate cancer: the role of hormonal treatment". Discovery Medicine. 7 (39): 118–24. PMID 18093474.
  81. ^ a b c d e f Jia AY, Spratt DE (June 2022). "Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative". Int J Radiat Oncol Biol Phys. 113 (2): 316–319. doi:10.1016/j.ijrobp.2022.01.037. PMID 35569476. S2CID 248765294. Four other randomized trials using BICmono have also raised concerns about either lack of efficacy or even harm from this treatment approach compared with placebo or no hormone therapy. SPCG-6 randomized 1218 patients to either 150 mg of BICmono daily or placebo. In the subset of patients with LPCa managed with observation, survival was significantly worse with BIC than placebo (hazard ratio [HR], 1.47; 95% confidence interval, 1.06-2.03).10 Two other randomized trials were part of the early prostate cancer program,11 which conducted 3 randomized trials that were pooled together to determine the benefit of BICmono (SPCG-6 was one of the 3 trials). Overall, in the combined 8113 patient pooled cohort, after a median follow-up of 7 years, there was no improvement even in progression-free survival from the use of adjuvant BIC in LPCa, and there was a trend for worse overall survival (HR, 1.16; 95% confidence interval, 0.99-1.37; P = .07). [...] Although not in LPCa, NRG/RTOG 9601 demonstrated findings consistent with the prior trials.12 This trial randomized men to postprostatectomy salvage radiation therapy plus placebo versus 150 mg of BICmono daily for 2 years. After a median follow-up of 13 years, the trial showed that there were significantly more grade 3 to 5 cardiac events in the BICmono arm. In patients with less aggressive disease with lower PSAs (prostate-specific antigens; more analogous to LPCa), other-cause mortality was significantly higher in the BICmono arm. In patients with high PSAs >1.5 ng/mL (which with modern molecular positron emission tomography imaging would be expected to have high rates of regional and distant metastatic disease), a survival benefit from the addition of BIC was observed. This is consistent with results from the early prostate cancer studies that showed that only patients with more advanced disease derived benefit from BICmono.10 Thus, all the randomized evidence from 5 trials (Table 1) demonstrates that, in LPCa, BICmono had no clinically significant oncologic activity over placebo/no treatment, and consistent trends with long-term use resulted in worse survival.
  82. ^ a b c d e Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK (2011). "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials". JAMA: The Journal of the American Medical Association. 306 (21): 2359–66. doi:10.1001/jama.2011.1745. PMID 22147380.
  83. ^ Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y (2014). "Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies". PLOS ONE. 9 (9): e107516. Bibcode:2014PLoSO...9j7516Z. doi:10.1371/journal.pone.0107516. PMC 4180271. PMID 25264674.
  84. ^ Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M (September 2015). "Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis". Eur Urol. 68 (3): 386–96. doi:10.1016/j.eururo.2014.11.039. PMID 25484142.
  85. ^ Poljak Z, Hulin I, Maruscakova L, Carter A, Mladosievicova B (2016). "Androgen deprivation therapy and cardiovascular complications". Bratisl Lek Listy. 117 (10): 557–561. doi:10.4149/BLL_2016_109. PMID 28621142.
  86. ^ Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E (June 2016). "Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies". Medicine (Baltimore). 95 (24): e3873. doi:10.1097/MD.0000000000003873. PMC 4998460. PMID 27310974.
  87. ^ Agarwal M, Canan T, Glover G, Thareja N, Akhondi A, Rosenberg J (August 2019). "Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer". Curr Oncol Rep. 21 (10): 91. doi:10.1007/s11912-019-0841-z. PMID 31446509. S2CID 201621193.
  88. ^ Hu JR, Duncan MS, Morgans AK, Brown JD, Meijers WC, Freiberg MS, Salem JE, Beckman JA, Moslehi JJ (March 2020). "Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses". Arterioscler. Thromb. Vasc. Biol. 40 (3): e55–e64. doi:10.1161/ATVBAHA.119.313046. PMC 7047549. PMID 31969015.
  89. ^ Kakarla M, Ausaja Gambo M, Yousri Salama M, Haidar Ismail N, Tavalla P, Uppal P, Mohammed SA, Rajashekar S, Giri Ravindran S, Hamid P (June 2022). "Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review". Cureus. 14 (6): e26209. doi:10.7759/cureus.26209. PMC 9307258. PMID 35891816.
  90. ^ Guirguis K (2016). "Bicalutamide causes heart failure in an elderly patient with prostate cancer". Expert Opin Drug Saf. 15 (3): 297–302. doi:10.1517/14740338.2015.1131819. PMID 26745594. S2CID 41053180.
  91. ^ a b Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, Barbot M, Scaroni C (December 2020). "Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS". Int J Mol Sci. 21 (24): 9554. doi:10.3390/ijms21249554. PMC 7765466. PMID 33334002.
  92. ^ a b Luque-Ramírez M, Ortiz-Flores AE, Nattero-Chávez L, Escobar-Morreale HF (December 2020). "A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy". Expert Opin Drug Saf. 19 (12): 1559–1576. doi:10.1080/14740338.2020.1839409. PMID 33070640. S2CID 224784192.
  93. ^ Eri LM, Urdal P (1995). "Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia". Eur Urol. 27 (4): 274–9. doi:10.1159/000475180. PMID 7544732.
  94. ^ Sawazaki H, Araki D, Kitamura Y, Yagi K (June 2020). "Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study". World J Urol. 38 (6): 1465–1471. doi:10.1007/s00345-019-02937-x. PMID 31482294. S2CID 201815162.
  95. ^ Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J (June 2019). "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (25): e1082–e1143. doi:10.1161/CIR.0000000000000625. PMC 7403606. PMID 30586774.
  96. ^ Coleman, E.; et al. (19 August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health. 23 (Suppl 1): S1–S259. doi:10.1080/26895269.2022.2100644. ISSN 2689-5269. PMC 9553112. PMID 36238954.
  97. ^ Baldani DP, Skrgatic L, Ougouag R, Kasum M (February 2018). "The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment". Gynecol Endocrinol. 34 (2): 87–91. doi:10.1080/09513590.2017.1381681. PMID 28944709. S2CID 205631980.
  98. ^ Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P (October 2009). "Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism". Br J Clin Pharmacol. 68 (4): 634–7. doi:10.1111/j.1365-2125.2009.03483.x. PMC 2780289. PMID 19843067.
  99. ^ Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
  100. ^ Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocr Rev. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
  101. ^ Jiang Y, Tian W (November 2017). "The effects of progesterones on blood lipids in hormone replacement therapy". Lipids Health Dis. 16 (1): 219. doi:10.1186/s12944-017-0612-5. PMC 5697110. PMID 29157280.
  102. ^ Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, Lambe M, Stattin P, Holmberg L (May 2010). "Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden". Lancet Oncol. 11 (5): 450–8. doi:10.1016/S1470-2045(10)70038-3. PMC 2861771. PMID 20395174.
  103. ^ Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L (July 2016). "Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism". Eur. Urol. 70 (1): 56–61. doi:10.1016/j.eururo.2015.06.022. PMID 26138040.
  104. ^ Seaman HE, Langley SE, Farmer RD, de Vries CS (June 2007). "Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database". BJU Int. 99 (6): 1398–403. doi:10.1111/j.1464-410X.2007.06859.x. PMID 17537215. S2CID 21350686.
  105. ^ Edmunds K, Tuffaha H, Galvão DA, Scuffham P, Newton RU (May 2020). "Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: a systematic literature review". Support Care Cancer. 28 (5): 2079–2093. doi:10.1007/s00520-019-05255-5. hdl:10072/391356. PMID 31912360. S2CID 209896933.
  106. ^ Nead KT, Boldbaatar N, Yang DD, Sinha S, Nguyen PL (April 2018). "Association of Androgen Deprivation Therapy and Thromboembolic Events: A Systematic Review and Meta-analysis". Urology. 114: 155–162. doi:10.1016/j.urology.2017.11.055. PMID 29352986. S2CID 4858605.
  107. ^ H.-L. Krüskemper (22 October 2013). Anabolic Steroids. Elsevier. pp. 75–. ISBN 978-1-4832-6504-9.
  108. ^ Kochakian, C. D. (1976). "Body and Organ Weights and Composition". Anabolic-Androgenic Steroids. pp. 73–154. doi:10.1007/978-3-642-66353-6_4. ISBN 978-3-642-66355-0.
  109. ^ Starka L, Broulik PD, Hampl R, Nedvidkova J, Hill M (June 1996). "Antirenotropic action of antiandrogens cyproterone acetate, casodex, flutamide and epitestosterone". Endocr Regul. 30 (2): 93–97. PMID 10979040.
  110. ^ Mooradian AD, Morley JE, Korenman SG (February 1987). "Biological actions of androgens". Endocr. Rev. 8 (1): 1–28. doi:10.1210/edrv-8-1-1. PMID 3549275.
  111. ^ a b c Peng CC, Chen CY, Chen CR, Chen CJ, Shen KH, Chen KC, Peng RY (March 2019). "Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model". Sci Rep. 9 (1): 3392. Bibcode:2019NatSR...9.3392P. doi:10.1038/s41598-019-39533-3. PMC 6399217. PMID 30833616.
  112. ^ a b c Saito S (March 2020). "Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer". Urol Case Rep. 29: 101108. doi:10.1016/j.eucr.2019.101108. PMC 6951477. PMID 31934548.
  113. ^ Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S (July 2013). "Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer". JAMA. 310 (3): 289–96. doi:10.1001/jama.2013.8638. PMID 23860987.
  114. ^ a b Kolvenbag GJ, Blackledge GR, Gotting-Smith K (January 1998). "Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development". Prostate. 34 (1): 61–72. doi:10.1002/(sici)1097-0045(19980101)34:1<61::aid-pros8>3.0.co;2-n. PMID 9428389. S2CID 22785559.
  115. ^ Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ (September 1997). "Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group". Urology. 50 (3): 330–6. doi:10.1016/s0090-4295(97)00279-3. PMID 9301693.
  116. ^ a b c Saltalamacchia G, Frascaroli M, Bernardo A, Quaquarini E (July 2020). "Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer". Cancers. 12 (7): 1750. doi:10.3390/cancers12071750. PMC 7407336. PMID 32630204.
  117. ^ a b c Masuda H (January 2023). "Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy". Anticancer Res. 43 (1): 305–309. doi:10.21873/anticanres.16164. PMID 36585176. S2CID 255265089.
  118. ^ a b Chen KC, Chen CR, Chen CY, Tzou KY, Peng CC, Peng RY (May 2020). "Bicalutamide Elicits Renal Damage by Causing Mitochondrial Dysfunction via ROS Damage and Upregulation of HIF-1". Int J Mol Sci. 21 (9): 3400. doi:10.3390/ijms21093400. PMC 7247665. PMID 32403414.
  119. ^ a b Chen KC, Chen CR, Chen CY, Peng CC, Peng RY (December 2021). "Bicalutamide Exhibits Potential to Damage Kidney via Destroying Complex I and Affecting Mitochondrial Dynamics". J Clin Med. 11 (1): 135. doi:10.3390/jcm11010135. PMC 8745250. PMID 35011880.
  120. ^ a b Peng CC, Chen CR, Chen CY, Chen KC, Peng RY (April 2022). "Bicalutamide may enhance kidney injury in diabetes by concomitantly damaging energy production from OXPHOS and glycolysis". Chem Biol Interact. 356: 109858. Bibcode:2022CBI...35609858P. doi:10.1016/j.cbi.2022.109858. PMID 35151640. S2CID 246767401.
  121. ^ a b Bruno Lunenfeld; Louis JG Gooren; Alvaro Morales; John Morley (20 December 2007). Textbook of Men's Health and Aging. CRC Press. pp. 258–. ISBN 978-0-203-08979-8.
  122. ^ a b c d William Llewellyn (2011). Anabolics. Molecular Nutrition Llc. pp. 34, 55. ISBN 978-0-9828280-1-4.
  123. ^ a b c d e f g McLeod DG (1997). "Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer". Oncologist. 2 (1): 18–27. doi:10.1634/theoncologist.2-1-18. PMID 10388026. Incidences of abnormal liver function test results have been variously reported from 2%-33% in nilutamide groups [13, 32, 33, 45] and from 4%-62% in flutamide groups [5, 7, 9, 11, 34, 38-40, 48] in trials of monotherapy and CAB. [...] In the double-blind, comparative study of flutamide plus LHRH-A versus bicalutamide plus LHRH-A, elevated transaminases occurred in slightly more patients in the flutamide group than in the bicalutamide group (10% versus 6%; p = 0.07). This increased incidence was also seen for patients with greatly elevated (>5× normal) transaminase values (2% versus 0.5%) [22, 46].
  124. ^ Diane S. Aschenbrenner; Samantha J. Venable (2009). Drug Therapy in Nursing. Lippincott Williams & Wilkins. pp. 629–. ISBN 978-0-7817-6587-9.
  125. ^ Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. pp. 789–. ISBN 978-0-323-34026-7.
  126. ^ Mangus BC, Miller MG (11 January 2005). Pharmacology Application in Athletic Training. F.A. Davis. pp. 151–. ISBN 978-0-8036-2027-8.
  127. ^ a b Oh WK (2001). "Anemia Related to Hormonal Ablation Therapy for Prostate Cancer". The Prostate Journal. 3 (1): 14–17. doi:10.1046/j.1525-1411.2001.003001014.x.
  128. ^ Schellhammer, Paul (December 1996). "Drug Evaluation Oncologic, Endocrine & Metabolic: Bicalutamide (Casodex™)". Expert Opinion on Investigational Drugs. 5 (12): 1707–1722. doi:10.1517/13543784.5.12.1707. eISSN 1744-7658. ISSN 1354-3784. Decreases in haemoglobin have been associated with flutamide therapy; more modest reductions occurred in patients who received bicalutamide in the monotherapy studies. In the combination study, flutamide therapy appeared to have a more profound negative effect on haemoglobin synthesis than did bicalutamide [24].
  129. ^ Khan AM, Singh NT, Bilgrami S (April 1997). "Flutamide induced methemoglobinemia". The Journal of Urology. 157 (4): 1363. doi:10.1016/s0022-5347(01)64982-6. PMID 9120948.
  130. ^ a b c d Hussain S, Haidar A, Bloom RE, Zayouna N, Piper MH, Jafri SM (2014). "Bicalutamide-induced hepatotoxicity: A rare adverse effect". Am J Case Rep. 15: 266–70. doi:10.12659/AJCR.890679. PMC 4068966. PMID 24967002.
  131. ^ See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al. (August 2002). "Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program". The Journal of Urology. 168 (2): 429–35. doi:10.1016/S0022-5347(05)64652-6. PMID 12131282.
  132. ^ "Casodex Product Monograph" (PDF). Retrieved 24 September 2018.
  133. ^ "NU-Bicalutamide Product Monograph" (PDF). Retrieved 24 September 2018.
  134. ^ a b c Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". Eur. Urol. 29 (Suppl 2): 96–104. doi:10.1159/000473847. PMID 8717470.
  135. ^ a b Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G (January 1996). "Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group". Urology. 47 (1A Suppl): 54–60, discussion 80–4. doi:10.1016/s0090-4295(96)80010-0. PMID 8560679. The tolerability evaluation included 808 patients (401 in the bicalutamide plus LHRH-A group and 407 in the flutamide plus LHRH-A group) and was performed after a median follow-up of 49 weeks. Five patients refused therapy; 88 patients (32 [8.0%] in the bicalutamide plus LHRH-A group and 56 [13.8%] in the flutamide plus LHRH-A group) had study therapy withdrawn because of safety reasons (Table II). [...] TABLE II. Adverse events leading to withdrawal: [...] Liver function abnormalities: Bicalutamide plus LHRH-A (n = 401): 6 [1.5%]; Flutamide plus LHRH-A (n = 407): 8 [2.0%]. [...]
  136. ^ a b Mahler C, Verhelst J, Denis L (May 1998). "Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer". Clinical Pharmacokinetics. 34 (5): 405–17. doi:10.2165/00003088-199834050-00005. PMID 9592622. S2CID 25200595.
  137. ^ See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ (August 2002). "Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program". J Urol. 168 (2): 429–35. doi:10.1016/S0022-5347(05)64652-6. PMID 12131282.
  138. ^ a b Carvalho RM, Santos LD, Ramos PM, Machado CJ, Acioly P, Frattini SC, Barcaui CB, Donda AL, Melo DF (October 2022). "Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know". J Cosmet Dermatol. 21 (10): 4171–4175. doi:10.1111/jocd.14773. PMID 35032336. S2CID 253239337.
  139. ^ Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R (November 2020). "Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients". J Am Acad Dermatol. 83 (5): 1478–1479. doi:10.1016/j.jaad.2020.03.034. PMID 32213304. S2CID 214683043.
  140. ^ a b Blackledge G, Kolvenbag G, Nash A (January 1996). "Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer". Anticancer Drugs. 7 (1): 27–34. doi:10.1097/00001813-199601000-00002. PMID 8742095.
  141. ^ a b Goa KL, Spencer CM (May 1998). "Bicalutamide in advanced prostate cancer. A review". Drugs Aging. 12 (5): 401–22. doi:10.2165/00002512-199812050-00006. PMID 9606617. S2CID 45943737.
  142. ^ Shipley, W.U.; Hunt, D.; Lukka, H.; Major, P.; Heney, N.M.; Grignon, D.; Patel, M.; Bahary, J.; Lawton, C.; Sandler, H. (November 2010). "Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels". International Journal of Radiation Oncology, Biology, Physics. 78 (3): S27. doi:10.1016/j.ijrobp.2010.07.103. ISSN 0360-3016. In the [radiation therapy (RT)] plus [anti-androgen Therapy (AAT)] arm Grade III was the highest liver toxicity observed which occurred in 3 of 387 patients.
  143. ^ Akaza H, Yamaguchi A, Matsuda T, Igawa M, Kumon H, Soeda A, Arai Y, Usami M, Naito S, Kanetake H, Ohashi Y (January 2004). "Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients". Jpn J Clin Oncol. 34 (1): 20–8. doi:10.1093/jjco/hyh001. PMID 15020659. Two patients in the MAB group had a grade 4 ADR relating to hepatic function, while one patient in each group had a grade 3 ADR. [...] Reassuringly in our study, neither the total number of patients with any abnormal hepatic function test result nor the frequency of elevations of individual enzymes was markedly higher in the MAB group than in the monotherapy group. However, as two grade 4 events did occur in the MAB group, we do recommend periodic testing of hepatic function.
  144. ^ Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T (April 2018). "A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma". Ann Oncol. 29 (4): 979–984. doi:10.1093/annonc/mdx771. PMC 5913639. PMID 29211833. Elevated grade 3 liver transaminases and increased serum creatinine were reported in two patients, respectively. [...] Regarding the grade 3 liver dysfunction patients, one incident was due to bicalutamide and another was due to liver metastasis progression.
  145. ^ Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA (October 2013). "Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer". Clin Cancer Res. 19 (19): 5505–12. doi:10.1158/1078-0432.CCR-12-3327. PMC 4086643. PMID 23965901. There were few grade 2 or 3 adverse events associated with bicalutamide (Table 3). All grade 3 liver enzyme abnormalities (elevation in AST, bilirubin, and alkaline phosphatase) were documented in 1 patient with known liver metastases who had progressed on therapy. Thus, it remains unclear whether these laboratory findings were attributable to bicalutamide therapy or disease progression.
  146. ^ Lehne RA (2013). Pharmacology for Nursing Care. Elsevier Health Sciences. pp. 1297–. ISBN 978-1-4377-3582-6.
  147. ^ Tripathi KD (30 September 2013). Essentials of Medical Pharmacology. JP Medical Ltd. pp. 302–. ISBN 978-93-5025-937-5.
  148. ^ Trüeb RM, Luu NC, Uribe NC, Régnier A (December 2022). "Comment on: Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know". J Cosmet Dermatol. 21 (12): 7200–7201. doi:10.1111/jocd.14936. PMID 35332669. S2CID 247677549. Indeed, due to the minimal biological importance of androgens in women, the adverse effects of bicalutamide are few. And yet, bicalutamide has been associated with elevated liver enzymes, and as of 2021, there have been 10 case reports of liver toxicity associated with bicalutamide, with fatality occurring in 2 cases.2
  149. ^ a b Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. (2018). "Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect". Case Reports in Gastroenterology. 12 (2): 266–270. doi:10.1159/000485175. hdl:20.500.11815/1492. ISSN 1662-0631.
  150. ^ a b Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, Kang SH, Moon HS, Sung JK, Lee HY, Kim KH (April 2016). "Atypical onset of bicalutamide-induced liver injury". World J. Gastroenterol. 22 (15): 4062–5. doi:10.3748/wjg.v22.i15.4062. PMC 4823258. PMID 27099451.
  151. ^ a b Ikemoto I, Kiyota H, Abe K, Hasegawa T, Ohishi Y, Aizawa Y (20 May 2000), "ビカルタミドにより惹起された重症肝障害" [Bicalutamide-induced Liver Toxicity in a Patient with Prostate Cancer], 臨床泌尿器科 [Rinsho Hinyokika (Clinical Urology)], 54: 489–491, doi:10.11477/mf.1413902997
  152. ^ Craig JV, Furr B (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 356–. ISBN 978-1-59259-152-7. A case of near-fatal fulminant hepatic failure in a patient on bicalutamide therapy (50 mg) has recently been published (101), but it is uncertain whether this can be attributed to bicalutamide, as the symptoms developed after only two doses in a patient previously exposed to both cyproterone acetate and flutamide (101).
  153. ^ a b "FDA Adverse Event Reporting System (FAERS) Public Dashboard". FDA. 22 October 2021.
  154. ^ Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A (April 2006). "Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system". Pharmacoepidemiol Drug Saf. 15 (4): 253–9. doi:10.1002/pds.1168. PMID 16294367. S2CID 24515447.
  155. ^ Jordan VC, Furr BJ (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 350–. ISBN 978-1-59259-152-7. Archived from the original on 29 May 2016.
  156. ^ a b Danseuse P, Snyder RR, Monks TJ, Jollow DJ, Sipes IG, Greim H, Gibson GG, Delaforge M (6 December 2012). Biological Reactive Intermediates Vi: Chemical and Biological Mechanisms in Susceptibility to and Prevention of Environmental Diseases. Springer Science & Business Media. pp. 37–. ISBN 978-1-4615-0667-6. Archived from the original on 28 April 2016.
  157. ^ Ramon J, Denis L (5 June 2007). Prostate Cancer. Springer Science & Business Media. pp. 256–. ISBN 978-3-540-40901-4. Archived from the original on 27 April 2016.
  158. ^ a b Kolvenbag, Geert J. C. M.; Furr, Barrington J.A. (2009). "Nonsteroidal Antiandrogens". Hormone Therapy in Breast and Prostate Cancer. Humana Press. pp. 347–368. doi:10.1007/978-1-59259-152-7_16. ISBN 978-1-60761-471-5. Differences between the NSAAs are also apparent with respect to liver toxicity. Abnormal liver-function tests have been reported with all three NSAAs. The incidence of abnormalities varies widely, from 2–3% with nilutamide (67,94,95) and 4–62% with flutamide (45,69,91,96–98). Many, but not all, cases may be at least partly due to underlying diseases and/or concomitant drug therapy. In the double-blind comparative study of flutamide and bicalutamide, the incidence of elevated transaminases was higher, but not significantly so, in the flutamide group (56). Symptomatic and, in some cases, serious hepatotoxicity has also been reported for NSAAs. It has been estimated that the risk of severe, potentially fatal, hepatic failure with flutamide is 3/10000 patients (99). Nilutamide hepatotoxicity is less well-documented, but can also have a fatal outcome (100).
  159. ^ Ricci F, Buzzatti G, Rubagotti A, Boccardo F (November 2014). "Safety of antiandrogen therapy for treating prostate cancer". Expert Opin Drug Saf. 13 (11): 1483–99. doi:10.1517/14740338.2014.966686. PMID 25270521. S2CID 207488100. Hepatotoxicity is a well-known complication of treatment with non-steroidal antiandrogens, as well as with Cyproterone acetate. The spectrum of drug-induced liver alterations is broad and encompasses the whole range of hepatic abnormalities. The incidence of abnormal liver-function tests has been reported in variable percentages, ranging from 4 to 62% of the patients treated with Flutamide in several trials comparing Flutamide, as part of MAB, versus castration [56-58].
  160. ^ a b c Kaplowitz N (16 October 2002). Drug-Induced Liver Disease. CRC Press. pp. 618–. ISBN 978-0-203-90912-6.
  161. ^ Kim JH, Yoo BW, Yang WJ (May 2014). "Hepatic failure induced by cyproterone acetate: A case report and literature review". Can Urol Assoc J. 8 (5–6): E458–61. doi:10.5489/cuaj.1753. PMC 4081269. PMID 25024808.
  162. ^ Bessone F, Lucena MI, Roma MG, Stephens C, Medina-Cáliz I, Frider B, Tsariktsian G, Hernández N, Bruguera M, Gualano G, Fassio E, Montero J, Reggiardo MV, Ferretti S, Colombato L, Tanno F, Ferrer J, Zeno L, Tanno H, Andrade RJ (February 2016). "Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases". Liver Int. 36 (2): 302–10. doi:10.1111/liv.12899. hdl:11336/52496. PMID 26104271. S2CID 33393791.
  163. ^ Gava, Giulia; Seracchioli, Renato; Meriggiola, Maria Cristina (2017). "Therapy with Antiandrogens in Gender Dysphoric Natal Males". Endocrinology of the Testis and Male Reproduction. pp. 1199–1209. doi:10.1007/978-3-319-44441-3_42. ISBN 978-3-319-44440-6. ISSN 2510-1927.
  164. ^ Andriole, Gerald L. (1996). "Discussion session: Clinical trials of bicalutamide as monotherapy for prostate cancer". Urology. 47 (1): 48–53. doi:10.1016/S0090-4295(96)80009-4. ISSN 0090-4295.
  165. ^ a b Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 169–. ISBN 978-1-60913-345-0.
  166. ^ a b Vinod Rustgi (16 November 2016). Drug Hepatotoxicity, An Issue of Clinics in Liver Disease, E-Book. Elsevier Health Sciences. pp. 89–. ISBN 978-0-323-49662-9.
  167. ^ Giorgetti R, di Muzio M, Giorgetti A, Girolami D, Borgia L, Tagliabracci A (2017). "Flutamide-induced hepatotoxicity: ethical and scientific issues". European Reviews for Medical and Pharmacological Sciences. 21 (1 Suppl): 69–77. PMID 28379593.
  168. ^ Bunce CM, Campbell MJ (11 March 2010). Nuclear Receptors: Current Concepts and Future Challenges. Springer Science & Business Media. pp. 160, 167. ISBN 978-90-481-3303-1. Archived from the original on 10 June 2016.
  169. ^ a b Coe KJ, Jia Y, Ho HK, Rademacher P, Bammler TK, Beyer RP, Farin FM, Woodke L, Plymate SR, Fausto N, Nelson SD (September 2007). "Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening". Chemical Research in Toxicology. 20 (9): 1277–90. doi:10.1021/tx7001349. PMC 2802183. PMID 17702527.
  170. ^ Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (June 2007). "Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants". Toxicological Sciences. 97 (2): 539–47. doi:10.1093/toxsci/kfm052. PMID 17361016. Apoptosis induced by the androgen antagonist bicalutamide is receptor mediated (Lin et al., 2006), and hence a dominant effect at low concentrations, and hepatoxicity is a rare event (Dawson et al., 1997), in accord with its relative lack of toxicity to galactose-grown cells.
  171. ^ Kashimshetty R, Desai VG, Kale VM, Lee T, Moland CL, Branham WS, New LS, Chan EC, Younis H, Boelsterli UA (July 2009). "Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity". Toxicology and Applied Pharmacology. 238 (2): 150–9. Bibcode:2009ToxAP.238..150K. doi:10.1016/j.taap.2009.05.007. PMID 19442681.
  172. ^ a b Ball AL, Kamalian L, Alfirevic A, Lyon JJ, Chadwick AE (July 2016). "Identification of the Additional Mitochondrial Liabilities of 2-Hydroxyflutamide When Compared With its Parent Compound, Flutamide in HepG2 Cells". Toxicological Sciences. 153 (2): 341–351. doi:10.1093/toxsci/kfw126. PMC 5036617. PMID 27413113.
  173. ^ Boelsterli UA, Ho HK, Zhou S, Leow KY (October 2006). "Bioactivation and hepatotoxicity of nitroaromatic drugs". Current Drug Metabolism. 7 (7): 715–27. doi:10.2174/138920006778520606. PMID 17073576.
  174. ^ Coe KJ, Nelson SD, Ulrich RG, He Y, Dai X, Cheng O, Caguyong M, Roberts CJ, Slatter JG (July 2006). "Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers". Drug Metab Dispos. 34 (7): 1266–75. doi:10.1124/dmd.105.009159. PMID 16611858. S2CID 8866215.
  175. ^ Gao X, Xie C, Wang Y, Luo Y, Yagai T, Sun D, Qin X, Krausz KW, Gonzalez FJ (November 2016). "The antiandrogen flutamide is a novel aryl hydrocarbon receptor ligand that disrupts bile acid homeostasis in mice through induction of Abcc4". Biochem Pharmacol. 119: 93–104. doi:10.1016/j.bcp.2016.08.021. PMC 5061623. PMID 27569425.
  176. ^ Chen CS, Gao GL, Ho DR, Lin CY, Chou YT, Chen SC, Huang MC, Kao WY, Su JJ (March 2021). "Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor". Sci Rep. 11 (1): 5457. Bibcode:2021NatSR..11.5457C. doi:10.1038/s41598-021-84769-7. PMC 7943802. PMID 33750846.
  177. ^ Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. (2018). "Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect". Case Reports in Gastroenterology. 12 (2): 266–270. doi:10.1159/000485175. ISSN 1662-0631. S2CID 81661015.
  178. ^ "Drug Record: Bicalutamide - LiverTox". National Library of Medicine. National Institutes of Health. Retrieved 13 November 2018.
  179. ^ Dart RC (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 497–. ISBN 978-0-7817-2845-4. Archived from the original on 11 May 2016.
  180. ^ a b Masago T, Watanabe T, Nemoto R, Motoda K (December 2011). "Interstitial pneumonitis induced by bicalutamide given for prostate cancer". International Journal of Clinical Oncology. 16 (6): 763–5. doi:10.1007/s10147-011-0239-x. PMID 21537882. S2CID 24068787.
  181. ^ Aronson JK (4 March 2014). Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions. Newnes. pp. 740–. ISBN 978-0-444-62636-3. Archived from the original on 6 May 2016.
  182. ^ Umeojiako WI, James M (2019). "Bicalutamide-induced Eosinophilic Pneumonitis-A Serendipitous Diagnosis". Journal of Case Reports in Medicine. 8 (1): 6. doi:10.25149/case-reports.v8i1.164. ISSN 2090-5351. S2CID 155609772.
  183. ^ Ricci F, Buzzatti G, Rubagotti A, Boccardo F (November 2014). "Safety of antiandrogen therapy for treating prostate cancer". Expert Opinion on Drug Safety. 13 (11): 1483–99. doi:10.1517/14740338.2014.966686. PMID 25270521. S2CID 207488100.
  184. ^ Gulley JL (2011). Prostate Cancer. Demos Medical Publishing. pp. 81–. ISBN 978-1-935281-91-7. Archived from the original on 25 April 2016.
  185. ^ Camus P, Rosenow III EC (29 October 2010). Drug-induced and Iatrogenic Respiratory Disease. CRC Press. pp. 235–. ISBN 978-1-4441-2869-7.
  186. ^ Rodriguez EM, Staffa JA, Graham DJ (2001). "The role of databases in drug postmarketing surveillance". Pharmacoepidemiology and Drug Safety. 10 (5): 407–10. doi:10.1002/pds.615. PMID 11802586. S2CID 21303661.
  187. ^ a b Wu B, Shen P, Yin X, Yu L, Wu F, Chen C, Li J, Xu T (February 2023). "Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System". Br J Clin Pharmacol. 89 (2): 440–448. doi:10.1111/bcp.15336. PMID 35349180. S2CID 247777754.
  188. ^ Matsumoto K, Nakao S, Hasegawa S, Matsui T, Shimada K, Mukai R, Tanaka M, Uranishi H, Nakamura M (2020). "Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database". SAGE Open Med. 8: 2050312120918264. doi:10.1177/2050312120918264. PMC 7262990. PMID 32528682.
  189. ^ a b Nawa H, Niimura T, Hamano H, Yagi K, Goda M, Zamami Y, Ishizawa K (2021). "Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects". Front Pharmacol. 12: 655605. doi:10.3389/fphar.2021.655605. PMC 8220081. PMID 34177574.
  190. ^ Dart RC (2004). Medical Toxicology. Lippincott Williams & Wilkins. pp. 497, 521. ISBN 978-0-7817-2845-4. Archived from the original on 11 May 2016.
  191. ^ Wong PW, Macris N, DiFabrizio L, Seriff NS (February 1998). "Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature". Chest. 113 (2): 548–50. doi:10.1378/chest.113.2.548. PMID 9498983.
  192. ^ Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA (June 2004). "Drug-induced pulmonary fibrosis". Saudi Medical Journal. 25 (6): 700–6. PMID 15195196.
  193. ^ Nargund VH, Raghavan D, Sandler HM (17 January 2015). Urological Oncology. Springer. pp. 823–. ISBN 978-0-85729-482-1. On the other hand, the 150 mg dose of bicalutamide has been associated with some safety concerns, such as a higher death rate when added to active surveillance in the early prostate cancer trialists group study [29], which has led the United States and Canada to recommend against prescribing the 150 mg dose [30].
  194. ^ Sternberg CN (2006). "Adjuvant bicalutamide for early prostate cancer: an update". Nature Clinical Practice Urology. 3 (8): 408–9. doi:10.1038/ncpuro0518. PMID 16902511. S2CID 2986301.
  195. ^ a b Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J (2006). "Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years". Scandinavian Journal of Urology and Nephrology. 40 (6): 441–52. doi:10.1080/00365590601017329. PMID 17130095. S2CID 25862814.
  196. ^ a b Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". Drugs. 66 (6): 837–50. doi:10.2165/00003495-200666060-00007. PMID 16706554. S2CID 46966712.
  197. ^ Iversen P, Roder MA (March 2008). "The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer". Expert Rev Anticancer Ther. 8 (3): 361–9. doi:10.1586/14737140.8.3.361. PMID 18366284. S2CID 207189398.
  198. ^ a b Stanworth RD, Jones TH (2008). "Testosterone for the aging male; current evidence and recommended practice". Clinical Interventions in Aging. 3 (1): 25–44. doi:10.2147/CIA.S190. PMC 2544367. PMID 18488876.
  199. ^ Strauss III JF, Barbieri RL (28 August 2013). Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Elsevier Health Sciences. pp. 688–. ISBN 978-1-4557-5972-9. Bone density improves in men receiving bicalutamide, most likely secondary to the 146% increase in estradiol and the fact that estradiol is the major mediator of bone density in men.
  200. ^ Marcus R, Feldman D, Nelson D, Rosen CJ (8 November 2007). Osteoporosis. Academic Press. pp. 1354–. ISBN 978-0-08-055347-4. Archived from the original on 11 June 2016.
  201. ^ Freedland SJ, Eastham J, Shore N (2009). "Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer". Prostate Cancer Prostatic Dis. 12 (4): 333–8. doi:10.1038/pcan.2009.35. PMID 19901933. S2CID 2580620.
  202. ^ Wibowo E, Schellhammer P, Wassersug RJ (January 2011). "Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy". J Urol. 185 (1): 17–23. doi:10.1016/j.juro.2010.08.094. PMID 21074215.
  203. ^ Wibowo E, Wassersug RJ (September 2013). "The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy". Crit Rev Oncol Hematol. 87 (3): 224–38. doi:10.1016/j.critrevonc.2013.01.006. PMID 23484454.
  204. ^ Coelingh Bennink HJ, Krijgh J, Egberts JF, Slootweg M, van Melick HH, Roos EP, Somford DM, Zimmerman Y, Schultz IJ, Clarke NW, van Moorselaar RJ, Debruyne FM (December 2022). "Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review". Endocr Connect. 11 (12). doi:10.1530/EC-22-0182. PMC 9716371. PMID 36283120.
  205. ^ a b Droz JP, Audisio RA (2 October 2012). Management of Urological Cancers in Older People. Springer Science & Business Media. pp. 84–. ISBN 978-0-85729-986-4. Archived from the original on 11 May 2016.
  206. ^ Mason M (August 2006). "What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?". Journal of Cancer Research and Clinical Oncology. 132: S27-35. doi:10.1007/s00432-006-0134-4. PMID 16896883. S2CID 19685819.
  207. ^ Cher ML, Honn KV, Raz A (11 April 2006). Prostate Cancer: New Horizons in Research and Treatment. Springer Science & Business Media. pp. 382–. ISBN 978-0-306-48143-7. Archived from the original on 5 May 2016.
  208. ^ Feldman D, Marcus R, Nelson D, Rosen CJ (8 November 2007). Osteoporosis. Academic Press. pp. 1354–. ISBN 978-0-08-055347-4. Archived from the original on 11 June 2016.
  209. ^ Vanderschueren D, Gaytant J, Boonen S, Venken K (June 2008). "Androgens and bone". Current Opinion in Endocrinology, Diabetes and Obesity. 15 (3): 250–4. doi:10.1097/MED.0b013e3282fe6ca9. PMID 18438173. S2CID 23851080.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Side_effects_of_bicalutamide&oldid=1256429240"